Stay updated on Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    No significant changes detected in core study information (enrollment, eligibility, sites, dosing, or outcomes). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T21:20:28.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    Major addition of a government funding notice and upgrade to v3.2.0, replacing v3.1.0; references to operating status and status inquiries are now present.
    Difference
    3%
    Check dated 2025-10-06T05:51:27.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    Updated contact details and a new software revision (v3.1.0) replacing the old v3.0.2; added multiple phone numbers and emails.
    Difference
    0.1%
    Check dated 2025-09-29T03:09:59.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed.
    Difference
    0.2%
    Check dated 2025-09-14T19:23:33.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.
    Difference
    0.2%
    Check dated 2025-09-07T16:26:07.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The web page has been updated to include new information about Hodgkins lymphoma and related treatments, with specific dates for updates and a revision to the facility name and location. Notably, the previous version's references to certain antineoplastic agents have been removed.
    Difference
    4%
    Check dated 2025-08-31T12:02:58.000Z thumbnail image

Stay in the know with updates to Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.